骨髄性白血病
- 関
- acute myeloid leukemia AML
WordNet
- malignant neoplasm of blood-forming tissues; characterized by abnormal proliferation of leukocytes; one of the four major types of cancer (同)leukaemia, leucaemia, cancer of the blood
PrepTutorEJDIC
- 白血病
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2012/10/10 12:34:37」(JST)
[Wiki en表示]
Myeloid leukemia |
Classification and external resources |
ICD-10 |
C92 |
ICD-9 |
205 |
ICD-O: |
M9860/3 |
MeSH |
D007951 |
Myeloid leukemia is a type of leukemia affecting myeloid tissue.
Types include:
- Acute myeloid leukemia
- Chronic myelogenous leukemia
See also
- Hematological malignancies
- Myeloblast
Myeloid hematological malignancy/leukemia histology (ICD-O 9590–9989, C81–C96, 200–208)
|
|
CFU-GM/
and other granulocytes |
CFU-GM
|
Myelocyte
|
AML: Acute myeloblastic leukemia (M0, M1, M2), APL/M3
MP (Chronic neutrophilic leukemia)
|
|
Monocyte
|
AML (AMoL/M5, Myeloid dendritic cell leukemia)
CML (Philadelphia chromosome, Accelerated phase chronic myelogenous leukemia)
|
|
Myelomonocyte
|
AML (M4)
MD-MP (Juvenile myelomonocytic leukemia, Chronic myelomonocytic leukemia)
|
|
Other
|
Histiocytosis
|
|
|
CFU-Baso
|
AML (Acute basophilic)
|
|
CFU-Eos
|
AML (Acute eosinophilic)
MP (Chronic eosinophilic leukemia/Hypereosinophilic syndrome)
|
|
|
MEP |
CFU-Meg
|
AML (AMKL/M7)
MP (Essential thrombocytosis)
|
|
CFU-E
|
AML (Erythroleukemia/M6)
MP (Polycythemia vera)
MD (Refractory anemia, Refractory anemia with excess of blasts, Chromosome 5q deletion syndrome, Sideroblastic anemia, Paroxysmal nocturnal hemoglobinuria, Refractory cytopenia with multilineage dysplasia)
|
|
|
CFU-Mast |
Mastocytoma (Mast cell leukemia, Mast cell sarcoma, Systemic mastocytosis)
Mastocytosis: Diffuse cutaneous mastocytosis · Erythrodermic mastocytosis · Generalized eruption of cutaneous mastocytosis (adult type) · Generalized eruption of cutaneous mastocytosis (childhood type) · Mast cell sarcoma · Solitary mastocytoma · Systemic mastocytosis · Xanthelasmoidal mastocytosis
|
|
Multiple/unknown |
AML (Acute panmyelosis with myelofibrosis, Myeloid sarcoma) · MP (Myelofibrosis) · Acute biphenotypic leukaemia
|
|
|
cell/phys (coag, heme, immu, gran), csfs
|
rbmg/mogr/tumr/hist, sysi/epon, btst
|
drug (B1/2/3+5+6), btst, trns
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Inhibitory effects of imatinib on vitamin D3 synthesis in human keratinocytes.
- Mehlig LM1, Garve C1, Tauer JT2, Suttorp M2, Bauer A1.
- Molecular medicine reports.Mol Med Rep.2015 Apr;11(4):3143-7. doi: 10.3892/mmr.2014.3074. Epub 2014 Dec 10.
- Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the presence of the BCR‑ABL1 fusion gene, a constitutively active, oncogenic tyrosine kinase that is responsible for the clinical features of CML. Tyrosine kinase inhibitors, such as imatinib, have markedly altered th
- PMID 25501030
- Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy.
- Lao Z1, Yiu R, Wong GC, Ho A.
- Asia-Pacific journal of clinical oncology.Asia Pac J Clin Oncol.2015 Mar;11(1):54-61. doi: 10.1111/ajco.12331. Epub 2014 Dec 28.
- AIMS: Azacitidine has been shown to prolong overall survival (OS) compared with best supportive care in elderly patients with acute myeloid leukemia (AML) with low blast counts but it is unknown if azacitidine has a similar efficacy in patients with blast counts of >30%. It is also unknown if aza
- PMID 25545192
- BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
- Faraoni I1, Compagnone M2, Lavorgna S3, Angelini DF4, Cencioni MT5, Piras E6, Panetta P7, Ottone T8, Dolci S9, Venditti A10, Graziani G11, Lo-Coco F12.
- Biochimica et biophysica acta.Biochim Biophys Acta.2015 Mar;1852(3):462-472. doi: 10.1016/j.bbadis.2014.12.001. Epub 2014 Dec 5.
- Olaparib (AZD-2281, Ku-0059436) is an orally bioavailable and well-tolerated poly(ADP-ribose) polymerase (PARP) inhibitor currently under investigation in patients with solid tumors. To study the clinical potential of olaparib as a single-agent for the treatment of acute myeloid leukemia (AML) patie
- PMID 25483710
Japanese Journal
- 白血病の分子標的治療と遺伝子検査 : 慢性骨髄性白血病のBCR-ABL検査の精度保証と適正利用 (第58回学術集会) -- (シンポジウム がんの分子標的治療と遺伝子検査)
- 宮地 勇人,松下 弘道,増川 敦子 [他]
- 臨床病理 : 日本臨床検査医学会誌 60(10), 982-987, 2012-10
- NAID 40019491103
- 急性骨髄性白血病に伴い歯肉と皮膚に生じた顆粒球肉腫の1例
- 白水 敬昌,寺沢 史誉,文 麻友美 [他]
- 日本口腔外科学会雑誌 = Japanese journal of oral and maxillofacial surgery 58(10), 595-599, 2012-10
- NAID 40019470103
Related Links
- Learn the dangers of benzene exposure its effects including acute myelogenous leukemia and acute lymphocytic leukemia. Contact a Benzene Lawyer here! ... Benzene has been widely used over the years, most greatly affecting workers ...
- Leukemia is a type of cancer that’s common in both kids and adults. Although depending on the kind of blood cells ... They say that prevention is better than cure, and while this applies even to minor illnesses, it’s even truer for life ...
Related Pictures
★リンクテーブル★
[★]
- 英
- myeloid leukemia, myelocytic leukemia, myelogenous leukemia
- 同
- ML
- 関
[★]
慢性単球性白血病
- 関
- granulocytic leukemia、myelocytic leukemia、myelogenous leukemia、myeloid leukemia
[★]
骨髄性白血病
- 関
- myelocytic leukemia、myelogenous leukemia、myeloid leukemia
[★]
急性骨髄性白血病 AML
[★]
慢性骨髄性白血病 CML
[★]
- 関
- myeloid